Profile data is unavailable for this security.
About the company
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.
- Revenue in EUR (TTM)5.45bn
- Net income in EUR240.00m
- Incorporated--
- Employees9.08k
- LocationUcb SAAllee de la Recherche, 60ANDERLECHT 1070BelgiumBEL
- Phone+32 25599999
- Fax+32 25599900
- Websitehttps://www.ucb.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Group AG | -107.67bn | -107.67bn | 18.84bn | 23.85k | -- | 2.30 | -- | -- | -- | -- | -- | 17.25 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.7401 | -- | 0.3469 | -- | 7.23 | -- | -90.92 | -- | -- | -- |
| Bayer AG | 46.74bn | -880.00m | 19.17bn | 100.87k | -- | 0.6275 | 2.64 | 0.4103 | -0.8957 | -0.8957 | 47.58 | 31.11 | 0.417 | 1.49 | 4.49 | 468,688.30 | -0.7815 | -1.79 | -1.06 | -2.38 | 57.14 | 59.02 | -1.87 | -4.80 | 0.8059 | 2.97 | 0.5728 | -- | -6.11 | 5.33 | -170.87 | -- | 1.19 | -47.66 |
| Zhangzhou Pientzhng Phrmctcl Co Ltd | 1.44bn | 406.20m | 19.54bn | 2.79k | 48.09 | 10.56 | -- | 13.58 | 5.10 | 5.10 | 18.08 | 23.24 | 0.6401 | 1.67 | 14.66 | 3,911,417.00 | 18.22 | 18.82 | 22.51 | 23.91 | 43.91 | 46.55 | 28.46 | 27.98 | 3.64 | -- | 0.0747 | 36.49 | 15.69 | 16.11 | 13.15 | 19.60 | 13.83 | 31.06 |
| Biogen Inc | 9.17bn | 1.54bn | 21.98bn | 7.57k | 14.28 | 1.40 | 10.17 | 2.40 | 11.07 | 11.07 | 65.83 | 112.90 | 0.34 | 0.8604 | 4.58 | 1,269,155.00 | 5.71 | 12.53 | 7.01 | 14.83 | 75.59 | 83.04 | 16.80 | 26.93 | 0.8039 | 4.89 | 0.2778 | 0.00 | -3.32 | -6.07 | -61.89 | -23.58 | -18.87 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.00bn | -317.21m | 30.39bn | 2.10k | -- | 982.81 | -- | 15.20 | -2.62 | -2.62 | 16.52 | 0.2511 | 0.5208 | 3.57 | 8.41 | 997,521.40 | -8.26 | -26.56 | -11.31 | -32.77 | 85.37 | 83.66 | -15.86 | -94.26 | 2.69 | -1.36 | 0.9694 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Otsuka Holdings Co Ltd | 14.02bn | 936.41m | 30.85bn | 34.39k | 32.03 | 1.93 | 18.98 | 2.20 | 279.51 | 279.51 | 4,183.34 | 4,641.15 | 0.647 | 2.40 | 4.68 | 65,998,690.00 | 4.42 | 4.80 | 5.59 | 5.88 | 71.42 | 68.21 | 6.84 | 8.36 | 1.53 | -- | 0.1173 | 42.16 | 16.14 | 9.33 | -9.18 | 8.07 | 9.27 | 1.92 |
| UCB SA | 5.45bn | 240.00m | 33.87bn | 9.08k | 141.56 | 3.69 | 36.27 | 6.21 | 1.23 | 1.23 | 27.92 | 47.19 | 0.3518 | 1.71 | 4.26 | 600,462.40 | 1.55 | 5.03 | 1.88 | 6.28 | 67.80 | 72.21 | 4.40 | 12.66 | 0.7806 | 3.15 | 0.2534 | 36.44 | -4.80 | 2.54 | -18.33 | -15.41 | -1.51 | 2.36 |
| Takeda Pharmaceutical Co Ltd | 28.09bn | 1.79bn | 40.50bn | 49.28k | 22.66 | 0.9439 | 6.25 | 1.44 | 181.90 | 181.90 | 2,862.68 | 4,365.91 | 0.3088 | 1.31 | 6.25 | 92,248,190.00 | 1.97 | 1.65 | 2.35 | 1.97 | 66.05 | 68.05 | 6.38 | 6.06 | 0.7739 | 3.08 | 0.4219 | 128.42 | 5.87 | 15.25 | -54.56 | 1.28 | 29.09 | 0.8735 |
| Haleon PLC | 13.51bn | 1.45bn | 40.52bn | 24.00k | 17.69 | -- | 179.33 | 3.00 | 0.2106 | 0.2106 | 1.44 | -- | -- | -- | -- | 468,333.30 | -- | -- | -- | -- | 61.94 | -- | 11.21 | -- | -- | 7.59 | -- | -- | 4.09 | -- | -1.04 | -- | -- | -- |
| Jiangsu Hengrui Pharmaceuticals Co Ltd | 3.43bn | 718.68m | 42.23bn | 19.61k | 59.06 | 7.32 | -- | 12.32 | 0.8499 | 0.8499 | 4.06 | 6.86 | 0.57 | 1.57 | 4.60 | 1,325,555.00 | 11.94 | 13.68 | 12.99 | 15.20 | 84.88 | 85.87 | 20.94 | 20.01 | 8.34 | -- | 0.002 | 23.77 | 7.26 | 5.55 | 10.14 | 1.14 | 22.90 | 9.45 |
| Sun Pharmaceutical Industries Ltd | 5.68bn | 1.25bn | 48.25bn | 43.00k | 38.59 | 6.18 | 31.20 | 8.49 | 46.12 | 46.12 | 209.89 | 288.06 | 0.6005 | 1.05 | 4.15 | 11,699,470.00 | 13.29 | 7.77 | 16.92 | 10.85 | 79.15 | 71.59 | 22.14 | 14.23 | 2.09 | -- | 0.0358 | 38.64 | 10.51 | 10.78 | 13.01 | 29.15 | -7.28 | 37.47 |
Data as of Nov 22 2024. Currency figures normalised to Ucb SA's reporting currency: Euro EUR
24.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 07 Nov 2024 | 15.99m | 8.22% |
| Wellington Management Co. LLPas of 14 May 2024 | 12.75m | 6.56% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 4.38m | 2.25% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 3.33m | 1.71% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 2.67m | 1.37% |
| Capital International Ltd.as of 07 Nov 2024 | 2.58m | 1.33% |
| BlackRock Investment Management (UK) Ltd.as of 13 Nov 2024 | 2.11m | 1.09% |
| Artisan Partners LPas of 30 Sep 2024 | 1.56m | 0.80% |
| Eleva Capital SASas of 30 Jun 2024 | 1.53m | 0.79% |
| BlackRock Advisors (UK) Ltd.as of 08 Nov 2024 | 1.44m | 0.74% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
